STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #334 by analyst upside · 2026-09-09
BIOA
BioAge Labs, Inc.
Healthcare · Market Cap $431M · P/E 0x
ANALYST PRICE TARGET
+279.2%
implied upside to consensus target
Current Price $9.39
Consensus Target $35.62
Bull Target $73.0
Bear Target $20.0
Analysts Covering 8
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
4
Hold
2
Sell
0
52-Week Low $4.68
52-Week High $25.95
YTD Return -26.8%
FUNDAMENTALS
Market Cap $431M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-2.39
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $10M
Profit Margin N/A
52-WEEK RANGE
52-Week Low $4.68
52-Week High $25.95
Current Price $9.39
Bear Target $20.0
Bull Target $73.0
● Now $9.39 ● Target $35.62
TRADING DATA
Avg Volume 883K
YTD Return -26.8%
Analyst Count 8
Consensus Buy
Upside to Target +279.2%
Last Updated 2026-09-09

ANALYST SUMMARY

BioAge Labs, Inc. (BIOA) is currently trading at $9.39 with a Wall Street consensus price target of $35.62, implying potential upside of 279.2% over the next 12 months. 8 analysts currently cover BIOA, with a consensus rating of Buy - 75% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $73.0, while the most cautious has a target of $20.0.

BIOA operates in the Healthcare sector with a market capitalisation of $431M. The stock is down 26.8% year-to-date and is currently trading near the lower end of its 52-week range of $4.68 – $25.95.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for BIOA, with each firm's 90-day track record across all stocks we track. See full firm rankings →

BTIG reit
Buy → Buy 2026-08-06 38% win rate (8 calls)
BTIG reit
Buy → Buy 2026-08-03 38% win rate (8 calls)
Needham - Reiterated
Buy → Buy 2026-07-31 20% win rate (5 calls)
Roth Capital ● Initiated
Buy 2026-05-27 Building track record
BTIG ● Initiated
Buy 2026-05-13 38% win rate (8 calls)
Needham ● Initiated
Buy 2026-03-27 20% win rate (5 calls)
Citigroup - Reiterated
Buy → Buy 2026-03-10 Building track record
Oppenheimer ● Initiated
Outperform 2026-02-25 14% win rate (7 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
31
out of 100
Coverage depth
17/30
Consensus clarity
0/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →